01119nas a2200205   4500000000100000008004100001653001200042653001600054653001200070653001300082653003800095100001700133700001100150700001200161245012500173856009600298300001000394490000700404520050200411       2018                            d10aDapsone10aHLA-B*13:0110aleprosy10aMalaysia10aSevere cutaneous adverse reaction1 aRamalingam R1 aToo CL1 aTang MM00aDapsone Hypersensitivity Syndrome and Dapsone-induced Liver Injury in Four Malaysian Indigenous Individuals with Leprosy  uhttp://www.dermatology.org.my/pdf/Malaysian_Journal_of_Dermatology_2018_05Jul18.pdf#page=75  a73-790 v403 a<p>Dapsone is part of the multi-drug therapy used in the treatment of leprosy. It can cause life-threatening hypersensitivity syndromes resulting in significant morbidity and mortality, especially among susceptible individuals such as those who are carriers of HLA-B*13:01 allele. Avoidance of dapsone in these susceptible individuals reduces the risk of dapsone-related adverse events. Herein, we report four indigenous patients with leprosy who developed dapsone hypersensitivity syndrome.</p>